| Item Type | Name |
|
Concept
|
Neoplasm Staging
|
|
Academic Article
|
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.
|
|
Academic Article
|
Malignant pleural mesothelioma.
|
|
Academic Article
|
Phase II study of flavopiridol in patients with advanced colorectal cancer.
|
|
Academic Article
|
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
|
|
Academic Article
|
Current state and future directions of pleural mesothelioma imaging.
|
|
Academic Article
|
A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.
|
|
Academic Article
|
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.
|
|
Academic Article
|
Malignant pleural mesothelioma: an update on biomarkers and treatment.
|
|
Academic Article
|
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
|
|
Academic Article
|
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
|
|
Academic Article
|
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
|
|
Academic Article
|
Personalized colon cancer care in 2010.
|
|
Academic Article
|
Robust data: the essential foundation of a revised staging system for pleural mesothelioma.
|
|
Academic Article
|
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
|
|
Academic Article
|
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
|
|
Academic Article
|
Optimization of response classification criteria for patients with malignant pleural mesothelioma.
|
|
Academic Article
|
The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Chemotherapy for advanced pancreatic cancer: past, present, and future.
|
|
Academic Article
|
Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
|
|
Academic Article
|
MARS: a sense of perspective and an inconvenient truth.
|
|
Academic Article
|
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
|
|
Academic Article
|
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
|
|
Academic Article
|
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
|
|
Academic Article
|
Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance.
|
|
Academic Article
|
Radiologic-pathologic correlation of mesothelioma tumor volume.
|
|
Academic Article
|
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
|
|
Academic Article
|
The Vulnerable Elders Survey-13 predicts mortality in older adults with later-stage colorectal cancer receiving chemotherapy: a prospective pilot study.
|
|
Academic Article
|
Current controversies in the stage-specific multidisciplinary management of pancreatic cancer.
|
|
Academic Article
|
Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance).
|
|
Academic Article
|
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
|
|
Academic Article
|
Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
|
|
Academic Article
|
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
|
|
Academic Article
|
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma.
|
|
Academic Article
|
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.
|
|
Academic Article
|
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.
|
|
Academic Article
|
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
|
|
Academic Article
|
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
|
|
Academic Article
|
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
|
|
Academic Article
|
Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance).
|
|
Academic Article
|
Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.
|
|
Academic Article
|
Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).
|
|
Academic Article
|
The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance).
|
|
Academic Article
|
Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance).
|
|
Academic Article
|
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
|